Company: SCLXW
Filing Date: 2025-12-29
Form Type: 424B3
Source: 0001193125-25-335429
Chunk: 282

Company: Scilex Holding Co
Filing Date: 2025-12-29
Form: 424B3
Chunk 282
---
1)– ITT Population

|                                         |     | SP-102  
 N=202   |                   |     | Placebo 
 N=199   |            |
| 30% reduction                           |     |         | 88 (43.6%)        |     |         | 57 (28.6%) |
| Chi-Square                              |     |         | P=0.002           |     |         |            |
| Logistic regression(2) (odds ratio [95% 
 CI])                                    |     |         | 1.96 (1.28, 2.98) |     |         |            |
|                                         |     | P=0.002 |                   |     |         |            |
| 50% reduction                           |     |         | 58 (28.7%)        |     |         | 41 (20.6%) |
| Chi-Square                              |     |         | P=0.060           |     |         |            |
| Logistic regression(2) (odds ratio [95% 
 CI])                                    |     |         | 1.58 (0.99, 2.52) |     |         |            |
| Chi-Square                              |     | P=0.055 |                   |     |         |            |

| (1) | Patients that discontinued or have missing scores at Week Four were considered 
 non-responders.                                                                |

| (2) | Logistic regression models with treatment (SP-102 or placebo), site,                                                                                         
 and Pain Catastrophizing Scale group (<30 or >30), and baseline averaged daily pain score as factors were used to compare the treatment groups at each week. |

CI: confidence interval; ITT: intent-to-treat(randomized population) Phase 2 Repeat Dose Study - SP-102-03 We conducted an open-label, single-arm,pharmacodynamics (“PD”) and tolerability study of repeat epidural injections of SP-102in patients with sciatica. We conducted this study to characterize repeat dose PD with respect to hypothalamic-pituitary-adrenal suppression using plasma cortisol levels, white blood cell count and blood glucose levels. The study enrolled 19 subjects, of which 15 received repeat SP-102epidural injections four to eight weeks after the initial injection. Four of the subjects did not experience recurrent pain and thus did not require a repeat injection. The daily average, current and worst pain in the affected leg and back